Navigation Links
Data From Three Clinical Studies of bioTheranostics' Breast Cancer Molecular Test Presented at CTRC-AACR San Antonio Breast Cancer Symposium
Date:12/12/2009

SAN DIEGO, Dec. 12 /PRNewswire/ -- bioTheranostics, a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from three studies using the company's breast cancer molecular test. Data from the studies were presented this week at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

The THEROS Breast Cancer Index® (BCI) is a combination of HOXB13:IL17BR (H/I) and Molecular Grade Index (MGI), biomarkers that improve risk stratification and treatment outcome prediction in patients with estrogen receptor (ER)-positive, lymph node-negative breast cancer. The majority of breast cancers diagnosed each year are ER-positive, lymph-node negative.

Data presented at the San Antonio meeting this week reinforce the value of the THEROS BCI as a tool that can help oncologists and patients make information-based decisions about breast cancer therapy. Specifically, the data demonstrate that the THEROS BCI assay provides reliable, quantitative and predictive information about individual patient's disease recurrence risk, as well as therapeutic response to a commonly used aromatase inhibitor.

Study Results

On Saturday, December 12, Olle Stal, PhD, of Linkoping University in Sweden, presented results from a large, randomized cohort study of 769 early-stage, post-menopausal breast cancer patients. Results of this study validated with statistical significance the risk prognosis ability of THEROS BCI in patients receiving tamoxifen monotherapy and no adjuvant treatment. In addition, the study demonstrated the value of the THEROS BCI assay as a continuous predictor for individual risk assessment. (Abstract #77)

"The predictive risk of recurrence provided by the THEROS BCI assay provides oncologists and patients with an objective and quantitative tool which helps them make informed decisions about breast cancer treatment," said Dr. Stal. "What is most important for us clinically is that the patients categorized by the BCI assay as 'low risk' had less than 4 percent chance of recurrence after 10 years." The ability to identify these low risk patients, who otherwise have pathological presentation similar to high risk patients, could significantly reduce the need for unnecessarily aggressive treatment in individual patients.

On Saturday, December 12, Laurie Habel, PhD, of Kaiser Permanente's Division of Research in Oakland, CA, presented data from a study evaluating the predictive performance of the BCI gene signatures (H/I and +MGI) among a large, independent population of 608 lymph node-negative breast cancer patients from a community hospital setting who either received tamoxifen or did not receive adjuvant therapy. Results suggest that, in this population of patients, the H/I and +MGI risk classifier is predictive of risk of breast cancer death. (Poster #4034)

Finally, on Friday, December 11, data were presented from a study in collaboration with Humphrey Gardner, MD of Novartis. These data demonstrate that the HOXB13 gene can predict response to neoadjuvant letrozole, an aromatase inhibitor, in patients with ER-positive breast cancer. Specifically, the data suggest that patients with low H/I have a three-fold greater response rate to letrozole as compared to patients with high H/I. This study reinforces the role of HOXB13 in the estrogen signaling pathway, and suggests that quantifying expression level of this gene could help physicians decide whether additional therapy is warranted in individual patients who have potentially low response rates to aromatase inhibitors. (Poster #2120)

"We are very excited about the outcome of these studies," said Richard Ding, chief executive officer of bioTheranostics. "Consistent with our previous work, this clinical evidence reinforces the clinical utility of the BCI assay. bioTheranostics is looking forward to providing this innovative diagnostic tool to clinicians to help improve risk-based and individualized treatment for breast cancer patients."

About bioTheranostics

Advancing Molecular Diagnostics in Oncology

bioTheranostics discovers, develops and commercializes molecular diagnostic tests for cancer patients. Leveraging its unique expertise in expression profiling and algorithm development, bioTheranostics provides innovative tests to the oncology community that drive personalized treatment. The company operates a CLIA-certified, CAP-accredited diagnostic service laboratory in San Diego, CA to perform its proprietary molecular diagnostic tests: the THEROS Breast Cancer Index®, that refines and improves risk stratification in patients with estrogen receptor (ER)-positive, lymph-node negative breast cancer; and the THEROS CancerTYPE ID test, a cancer classification assay that provides molecular classification of uncertain or unknown cancers to guide physicians in determination of the primary cancer site and aides in the selection of therapeutic options. For more information call 1-858-587-5870 or visit www.bioTheranostics.com.


    bioTheranostics Contacts
    Wendy Johnson
    Tel:  1 858 587 5887
    Wendy.Johnson@biotheranostics.com

    Michele Parisi
    Tel : 1 925 864 5028
    mparisi@biocommnetwork.com

About bioMerieux

Advancing Diagnostics to Improve Public Health

A world leader in the field of in vitro diagnostics for over 45 years, bioMerieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2008, revenues reached over euro 1.111 billion with 84% of sales outside of France.

bioMerieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cardiovascular emergencies and cancer screening and monitoring. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMerieux is listed on the NYSE Euronext Paris market (Code: BIM - Code ISIN: FR0010096479). Other information can be found at www.biomerieux.com.


    bioMerieux Contact
    Koren Wolman-Tardy
    Tel: + 011 33 6 13 94 51 14
    media@eu.biomerieux.com

SOURCE bioTheranostics


'/>"/>
SOURCE bioTheranostics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites
2. instaCare Corp. Continues Turnaround, Reports 58% Revenues Increase for First Three Quarters
3. Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
4. Osteotech Highlights Three Procedure-Specific MagniFuse(TM) Bone Grafting Products at the NASS 2009 Annual Meeting
5. AMD LASERS Announces Partnerships With Three Industry-Leading Companies
6. Three Cetaphil(R) Products Earn Good Housekeeping Seal
7. Hanger Orthopedic Group, Inc. Announces Three Acquisitions Totaling $10.7 Million of Annual Net Revenue
8. Cord Blood America Continues to Reduce Debt; Three Notes Retired
9. Novant Health Rolls Out MEDais Predictive Modeling Solution to Nine Hospitals in Three States
10. Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
11. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, 2016 ... mobile pulmonary function testing company, is now able to perform sophisticated ... by ndd Medical Technologies , Inc. Patients ... hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients ... get any needed testing done in the comfort of her own ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on ... Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ability ... fumigation is not a common occurrence, but a necessary one in the event that lice ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
Breaking Medicine News(10 mins):